SUPPLEMENTARY DIGITAL MATERIAL 7

Supplementary	Table VIIOu	ality assessment of included	d recommendations using the AGRE-REX tool.

N°	Recommendation					AGRI	EE-RE	X				Scoring justification	Source
		Item 1. Evidence	Item 2. Applicability to Target Users	Item 3. Applicability to Patients/Populations	Item 4. Values and Preferences of Target Users	Item 5. Values and Preferences of Patients/Populations	Item 6. Values and Preferences of Policy/Decision-Makers	Item 7. Values and Preferences of	Undeline Developers Item 8. Purpose	Item 9. Local Application and Adoption	Average		Guideline short title, chapter, page
	1.4.6 If an older person with a traumatic injury is on a care pathway that does not routinely involve geriatrician support, consider referral to an orthogeriatrician, a surgical liaison or a perioperative physician (as appropriate).		5	4	1	1	1	7	7	4	3,7	 *Item 1: The committee used their experience to recommend that older people have access to orthogeriatricians, surgical support or perioperative physicians. Doesn't assess any risk of bias related to the study designs of the supporting evidence, nor describes the consistency of the results. No reference is made, or in a superficial way, to this item. The recommendation does not describe the consistency of the results, publication bias, although it addresses the directness of the evidence to the clinical/health problem. The guideline does not describe the magnitude of the benefits and harms of this recommendation. *Item 2: The recommendations address a health problem that is relevant to the intended target users. Also there is an alignment between target user's scope of practice and targeted patients *Item 3: The guideline includes outcomes that are relevant to the targeted patients/populations. Also this recommendation describes how to tailor recommendations for application to individual patients or populations (e.g., based on age). *Item 4: It is not clear that they directly assess the values and preferences of the guide's target users. *Item 6: The values and preferences of decision/policy makers are not addressed in a direct way. *Item 7: The committee used their experience to formulate this recommendation. The recommendations in this guideline represent the view of NICE. *Item 8: This recommendation is aligned with the implementation goals of the guideline *Item 9: It is not clear that the recommendation assessed the setting, and/or the health system in which they are being implemented. 	NICE_Rehabilitation, 2022 Chapter: 1.4 Developing a rehabilitation plan and making referrals Page: 27
	1.4.7 For adults with a fragility fracture, assess bone health and refer as necessary, for example, to a specialist bone health clinic or outpatient service. Also see the NICE guideline on osteoporosis.	1	6	1	1	1	1	4	3	3	2,3	 Figure 1: Evidence searches for general topics such as the rehabilitation needs of people with spinal cord injury are presented, but there are no specific searches to reach individual recommendations such as bone health assessment. Or at least the authors don't mention this information in any of the sections of the guideline or in the supplements. *Item 2: The guideline addresses a health problem that is relevant to the intended target users. There is an alignment between target user's scope of practice and targeted populations. *Item 3: The authors did not describe the outcome information they analyzed to formulate the recommendation in the guideline document or in the supplements. *Item 4: It is not clear that the authors assessed the values and preferences of the guidelines target users. *Item 5: It is not clear that the values and preferences of the patients were sought or considered. *Item 7: The authors state "The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available". However there is not a clear description of how guideline developer's values and preferences influenced their interpretation of the balance between benefits and harms. *Item 8: This recommendation is aligned with the implementation goals of the guideline. A section on "How the recommendations might affect services" for Recommendations 1.4.1 to 1.4.11 is presented (pg 	NICE_Rehabilitation, 2022 Chapter: 1.4 Developing a rehabilitation plan and making referrals Page: 27

					1	1		1	-	1			
										1		97), but in a very general manner. The anticipated impacts of recommendation adoption on individuals,	
												organizations, and/or systems are not described.	
												*Item 9: It is not clear that the guideline developers considered the issues that can influence the adoption	
												of the recommendations. At the end of the guideline (pg 135), there is a link to NICE tools and resource	
												to help users put this guideline into practice. However the provided tools are common for all NICE	
												guidelines and set out the common steps taken when putting evidence-based guidance into practice.	
3	1.4.9 Assess all adults over 65	1	5	5	1	1	1	7	6	4	3,4	*Item 1: The recommendation doesn't assess any risk of bias related to the study designs of the supporting	g NICE_Rehabilitation, 2022
	who have a traumatic injury for											evidence, nor describes the consistency of the results.	Chapter: 1.4Developing a
	their risk of falls in line with the											*Item 2: The recommendations address a health problem that is relevant to the intended target users. Als	
	recommendations on											there is an alignment between target user's scope of practice and targeted patients	referrals
	multifactorial risk assessment in											*Item 3: The guideline includes outcomes that are relevant to the targeted patients/populations. Also this	
													rage. 27
	the NICE guideline on falls.											recommendation describes how to tailor recommendations for application to individual patients or	
												populations (e.g., based on age).	
												*Item 4: It is not clear that they directly assess the values and preferences of the guide's target users.	
												*Item 5: The values and preferences of the target population have not been sought or considered.	
												*Item 6: The values and preferences of decision/policy makers are not addressed directly.	
												*Item 7: The committee used their experience to did this recommendation. The recommendations in this	
				1		1				1		guideline represent the view of NICE.	
1				1		1				1		*Item 8: This recommendation is aligned with the implementation goals of the guideline	
												*Item 9: It is not clear that the recommendation assessed the setting, and/or the health system in which	
												they are being implemented.	
4	1 11 20 D that	4	4	7	4			7	7	-	5.4		NICE Rehabilitation. 2022
4	1.11.30 Be aware that spinal	4	4	/	4	0	3	'	/	<i>'</i>	5,4	*Item 1: The committee combined the available evidence with their experience and knowledge. The	
	orthoses, such as cervical collars and thoracolumbar spinal orthoses, may be poorly											guideline addresses the directness of the evidence of the orthosis however not the toleration of the ortho	
												*Item 2: The recommendations address a health problem that is relevant to the intended target users. Bu	Page: 57
												there is not alignment between target user's scope of practice and targeted patients	
	tolerated by some people,											*Item 3: The recommendation includes outcomes that are relevant to the targeted patients/populations.	
	particularly older people or those											They addressed an specific population (old)	
	with delirium, cognitive											*Item 4: It is not clear that they directly assess the values and preferences of the guide's target users.	
	impairment or dementia.											*Item 5: The values and preferences of the target population have not been sought or considered.	
	1											However, they say that People (and families and carers, if appropriate) should receive education on how	
												to wear splints or orthoses to limit adverse effects	
												*Item 6: The values and preferences of decision/policy makers are not addressed.	
												*Item 7: Evidence showed that spinal orthoses can help improve patient rehabilitation outcomes, and th	X7
												are used in current practice. However, in the committee's experience, not all trauma populations see a	y
												benefit (for example, older people) and spinal orthoses can cause adverse events if improperly fitted.	
												*Item 8: This recommendation is aligned with the implementation goals of the guideline	
												*Item 9: The recommendation assessed the setting, and/or the health system in which they are being	
												implemented. The recommendation reflect current practice because Splints and orthoses are commonly	
												used and are all low cost.	
5	1.11.17 Do not withhold aerobic	1	6	6	1	1	1	7	6	4	3,7	*Item 1: The recommendation doesn't assess any risk of bias related to the study designs of the supporting	g NICE Rehabilitation, 2022
	exercise programmes from older											evidence, nor describes the consistency of the results.	Chapter: 1.11 Physical rehabilitation
	people after a traumatic injury.											*Item 2: The recommendations address a health problem that is relevant to the intended target users. Als	
	people alter a traumate injury.											there is an alignment between target user's scope of practice and targeted patients	, i uge. 00
												*Item 3: The guideline includes outcomes that are relevant to the targeted patients/populations. Also this	
1				1		1				1			
												recommendation describes how to tailor recommendations for application to individual patients or	
				1		1				1		populations (e.g., based on age). Outcomes: optimize respiratory function, increase endurance when doin	g
												rehabilitation	
1				1		1				1		exercises, and improve mobility.	
1				1		1				1		*Item 4: It is not clear that they directly assess the values and preferences of the guide's target users.	
				1		1				1		*Item 5: The values and preferences of the target population have not been sought or considered.	
1				1		1				1		*Item 6: The values and preferences of decision/policy makers are not addressed directly.	
l I				1		1				1		*Item 7: The committee used their experience to did this recommendation. The recommendations in this	
	1			[1	1	1	1		1			
												guideline represent the view of NICE. *Item 8: This recommendation is aligned with the implementation goals of the guideline	
												*Item 8: This recommendation is aligned with the implementation goals of the guideline *Item 9: It is not clear that the recommendation assessed the setting, and/or the health system in which	

										they are being implemented. They say about this recommendation are not expected to have a significant	
1.11.49 For people with a fragility fracture, measure vitamin D levels and consider a supplement. Also see the recommendations in the NICE guideline on osteoporosis: assessing the risk of fragility fracture and the NICE guideline on vitamin D: supplement use in specific population groups.	1 6	1	1	1		4	3	3	2,:	injury are presented, but there are no specific searches to reach individual recommendations such as be health assessment. Or at least the authors don't mention this information in any of the sections of the guideline or in the supplements. *Item 2: The guideline addresses a health problem that is relevant to the intended target users. There is alignment between target user's scope of practice and targeted populations. *Item 3: The authors did not describe the outcome information they analyzed to formulate the recommendation in the guideline document or in the supplements. *Item 5: It is not clear that the authors assessed the values and preferences of the guidelines target user *Item 5: It is not clear that the values and preferences of the patients were sought or considered. *Item 6: It is not clear that the values and preferences of decision/policy makers were directily address *Item 7: The authors state "The recommendations in this guideline represent the view of NICE, arrive after careful consideration of the evidence available". However there is not a clear description of how guideline developer's values and preferences influenced their interpretation of the balance between benefits and harms. *Item 8: This recommendation is aligned with the implementation goals of the guideline. A section on "How the recommendations might affect services" for Recommendations 1.4.1 to 1.4.11 is presented (97), but in a very general manner. The anticipated impacts of recommendation adoption on individuals organizations, and/or systems are not described. *Item 9: It is not clear that the guideline developers considered the issues that can influence the adopti of the recommendations. At the end of the guideline (pg 135), there is a link to NICE tools and resourt to help users put this guideline into practice. However the provided tools are common for all NICE	e Chapter: 1.11 Physical rehabilitatio Page: 60 d. at g
1.11.47 Following assessment by a dietician specialising in trauma care, consider supplementation of dietary protein for people who are frail, have gastrointestinal health issues or have multiple injuries.	3 6	4	1	1	1	7	5	5	3,	 guidelines and set out the common steps taken when putting evidence-based guidance into practice. *Item 1: The committee agreed that there is a lack of awareness about the nutritional risks and needs following traumatic injury. The recommendation don't assess any risk of bias related to the study desig of the supporting evidence, not describes the consistency of the results. *Item 2: The recommendations address a health problem that is relevant to the intended target users. A there is an alignment between target user's scope of practice and targeted patients *Item 3: The outcomes that are relevant to the targeted patients/populations are not clear. but this recommendation describes how to tailor recommendations for application to individual patients or populations (e.g., Individuals who are frail). *Item 4: It is not clear that they directly assess the values and preferences of the directly.guide's targe users. *Item 7: The values and preferences of the target population have not been sought or considered. *Item 7: The committee used their experience to did this recommendation. The recommendations in th guideline represent the view of NICE. *Item 8: This recommendation is aligned with the implementation goals of the guideline *Item 9: It is not clear that the recommendation assessed the setting, and/or the health system in which they are being implemented. 'The recommendations are in line with current practice and will not need additional resources to implement'. 	Page: 60
1.15.21 For people with a spinal 5 cord injury who are using a spinal orthosis (for example, cervical collar or thoraco-lumbar spinal orthosis), regularly assess them for complications such as pain, pressure sores, swallowing or breathing difficulties (particularly in older people or those with dementia or delirium).	5 6	7	5	4	3	6	7	6	5,4	 *Item 1: The committee combined the available evidence with their experience and knowledge. The guideline addresses the directness of the evidence of the orthosis, however the outcomes are not direct addressed. *Item 2: The recommendations address a health problem that is relevant to the intended target users. *Item 3: The recommendation includes outcomes that are relevant to the targeted patients/populations. They addressed an specific population (old) *Item 4: It is not clear that they directly assess the values and preferences of the guide's target users. *Item 5: The values and preferences of the target population have not been sought or considered. *Item 6: The values and preferences of decision/policy makers are not addressed. *Item 7: Evidence showed that spinal orthoses can help improve patient rehabilitation outcomes, and are used in current practice. However, in the committee's experience, not all trauma populations see a benefit (for example, older people) and spinal orthoses can cause adverse events if improperly fitted. *Item 8: This recommendation is aligned with the implementation goals of the guideline. The committee's experience is a spinal orthose is a spinal orthose is can be and verse events if improperly fitted. 	spinal cord inju Page: 77

					1							consideration of the second se			
												agreed that it is important to maintain mobility and range of motion after a spinal cord injury.			
												*Item 9: The recommendation assessed the setting, and/or the health system in which they are being			
							_					implemented. They approach the costs item: some equipment, like robotics, can be expensive.			
9		3	6	1	1	1	1	1	3	3	2,2	*Item 1: The guideline reported a rationale for the recommendation. However, the guideline did not	Consortium_Bone		
	context of bone health screening,											describe the consistency of the results (i.e., similarity of results across studies), the directness of the	Chapter: 2. La	boratory	screening
	all adult women and men with											evidence, the precision of the results, the magnitude of the benefits and harms, the likelihood of	Page: 27		
	spinal cord injury (SCI),											publication bias, the possibility of confounding factors.	e		
	regardless of injury duration,											*Item 2: The guideline addresses a health problem that is relevant to the intended target users and there is			
	should have measurements of											an alignment between target user's scope of practice and targeted populations.			
	serum 25-hydroxyvitamin D (25-											*Item 3: The recommendation assessed does not include outcomes (It's a general recommendation for lab			
	(OH)D) done by a validated											testing for bone health screening). Also, the guideline does not report how the importance of outcomes to			
	assay method; complete blood											patients was determined.			
												L			
	cell count; ionized calcium (or											*Item 4: It is not clear that the authors assessed the values and preferences of the guidelines target users.			
	calcium adjusted for albumin),											*Item 5: It is not clear that the values and preferences of the patients were sought or considered.			
	phosphate, intact parathyroid											*Item 6: It is not clear that the values and preferences of decision/policy makers were directily addressed.			
	hormone, creatinine (and											*Item 7: A clear description of the values and preferences that guideline developers brought to the			
	estimated glomerular filtration											development process or how values and preferences influenced their interpretation of the balance between			
	rate), bone-specific alkaline											benefits and harms is lacking.			
	phosphatase and transaminases,											*Item 8: The guideline recommendations align with the implementation goals of the guideline. The			
	hemoglobin A1C, and thyroid-											anticipated impacts of recommendation adoption on individuals, organizations, and/or systems are not			
	stimulating hormone levels; and											described.			
	24-hour urine collection for											*Item 9: The guideline developers are aware of the implementation challenges and make a general advice			
	calcium and creatinine excretion.														
	calcium and creatinine excretion.											for guideline implementers: "Successful implementation of this guideline requires health care			
												professionals to partner with individuals with SCI/D and negotiate a joint understanding of their health,			
	Clinical Consideration											bone density results, and risk factors for fracture in order to enable selection of a mutually agreeable			
	2.1											treatment plan tailored to the individual's impairments, health preferences, and resources". However, it is			
	These laboratory measurements											not clear that the guideline describes the degree of change required from current practice or articulates			
	should be done as soon as											relevant factors important to its successful dissemination.			
	possible after the patient														
	establishes ongoing care with														
	their physician, or if there is														
	significant loss of bone mineral														
	density, an incident fracture, or a														
	change in a medical condition or														
	medication that might be														
	expected to influence														
	osteoporosis risk.														
	Referral to an endocrinologist or														
	appropriate subspecialist should														
	be considered if there are														
	unexplained serum or urine														
	calcium levels (hyper or hypo)														
	and/or if the workup is														
	suggestive of hyperthyroidism or														
	hyperparathyroidism. Referral to														
	a nephrologist should be														
	considered in those with chronic														
	kidney disease stage 4 (CKD 4)														
	(glomerular filtration rate [GFR]														
	15-29 mL/min) and CKD 5														
	(GFR 15 mL/min or less) or														
	unexplained renal impairment.														
10	3.1 We recommend that	3	6	1	1	1	1	1	3	3	2,2	*Item 1: The guideline reported a rationale for the recommendation. However, the guideline did not	Consortium_Bone	health	, 2022
-	clinicians adhere to the 2019										,	describe the consistency of the results (i.e., similarity of results across studies), the directness of the	Chapter: 3. Bone		
	ISCD Adult Official Positions											evidence, the precision of the results, the magnitude of the benefits and harms, the likelihood of	Empler. 5. Bolie	(0)	
L	HISCH Addit Official I Ostuolis					1	1			1		evidence, the procision of the results, the magnitude of the benefits and namis, the intermitted of	1		

for Dual-energy X-ray	publication bias, the possibility of confounding factors. dual-energy X-ray absorption
absorptionetry in Patients with	*Item 2: The guideline addresses a health problem that is relevant to the intended target users and there is Page: 36
Spinal Cord Injury.	an alignment between target user's scope of practice and targeted populations.
Spinar Cord Injury.	
	*Item 3: The recommendation assessed does not include outcomes (It's a general recommendation for
	bone density testing). Also, the guideline does not report how the importance of outcomes to patients was determined.
	*Item 4: It is not clear that the authors assessed the values and preferences of the guidelines target users.
	*Item 5: It is not clear that the values and preferences of the patients were sought or considered.
	*Item 6: It is not clear that the values and preferences of decision/policy makers were directily addressed.
	*Item 7: A clear description of the values and preferences that guideline developers brought to the
	development process or how values and preferences influenced their interpretation of the balance between
	benefits and harms is lacking.
	*Item 8: The guideline recommendations align with the implementation goals of the guideline. The
	anticipated impacts of recommendation adoption on individuals, organizations, and/or systems are not
	described.
	*Item 9: The guideline developers are aware of the implementation challenges and make a general advice
	for guideline implementers: "Successful implementation of the enclosed recommendations and ISCD
	Positions will require the SCI community to work collaboratively with health policymakers and payers to
	resolve feasibility dilemmas regarding bone density testing and the identification of patients with low bone
	mass or sublesional osteoporosis and high fracture risk who require therapy". However, it is not clear that
	the guideline describes the degree of change required from current practice or articulates relevant factors
	important to its successful dissemination.
11 5.2 The following are 6 6 7 1	6 7 5 4,4 *Item 1: In general, they have a good review of the quality and results of the available evidence. Consortium_Bone health, 2
recommendations for calcium	*Item 2: The recommendations address a health problem that is relevant to the intended target users. Also Chapter: 5. Calcium and vitamin
intake as a combination of food	there is an alignment between target user's scope of practice and targeted patients diet or supplem
and supplements (preference for	*Item 3: The guideline includes outcomes that are relevant to the targeted patients/populations in the Page: 48
dietary intake over supplements).	clinical consideration section page 48.
Group and age calcium	*Item 4: It is not clear that they directly assess the values and preferences of the guide's target users.
recommendation:	*Item 5: The values and preferences of the target population have not been sought or considered.
Men and premenopausal women	*Item 6: The values and preferences of decision/policy makers are not addressed.
age 19-50 years: 1,000 mg/day	*Item 7: Members of the Bone Health and Osteoporosis Management Clinical Expert Panel formulated
Men 50-70 years: 1,000 mg/day	key questions (to guide the literature search and study inclusion) related to prevalence, assessment, and
Women 50-70 years: 1,000-	treatment of bone health in the spinal cord injury (SCI) population.
1,200 mg/day	*Item 8: This recommendation is aligned with the implementation goals of the guideline
Men and women 71+ years:	*Item 9: It is not clear that the recommendation assessed the health system
1,000-1,200 mg/day	
Not appropriate for individuals	
who are found to be	
hypercalcemic.	
12 1. Regular monitoring of the 3 6 1 1	1 3 3 2,3 *Item 1: The guideline reported a brief introduction for the recommendation. However, the guideline did German speaking society_Life
cardiometabolic syndrome	not describe the evidence to support the recommendation. It is no clear that the consistency of the results follow-up,
should be carried out as part of	(i.e., similarity of results across studies), the directness of the evidence, the precision of the results, the Chapter: 3.3 Cardiovascular dise
lifelong follow-up in persons	magnitude of the benefits and harms, the likelihood of publication bias, the possibility of confounding Page: 16
with SCI (to be carried out by	factors were analyzed.
the general practitioner,	*Item 2: The guideline addresses a health problem that is relevant to the intended target users and there is
depending on the care situation).	an alignment between target user's scope of practice and targeted populations.
aspending on the out o brandon).	*Item 3: The recommendation assessed does not include outcomes. Apparently the only outcome was the
With increasing age, also the risk	lifelong follow-up of patients. It is not clear if the guideline evaluated the importance of outcomes to
of cardiovascular disease	patients.
increases.	*Item 4: It is not clear that the authors assessed the values and preferences of the guidelines target users.
	*Item 5: Although the authors mention that patient preferences were taking into account in the REPORT
The longer the SCI, the greater	document (Pg 18) there is no information on how this was considered for the recommendation.
the loss of lean mass.°	*Item 6: It is not clear that the values and preferences of decision/policy makers were directily addressed.
	*Item 7: A clear description of the values and preferences that guideline developers brought to the
	development process or how values and preferences influenced their interpretation of the balance between
	benefits and harms is lacking.

												*Item 8: The guideline recommendations align with the implementation goals of the guideline. The anticipated impacts of recommendation adoption on individuals, organizations, and/or systems are not described. *Item 9: The guideline developers state in the REPORT document (pg 19) that "In order to ensure the transfer of knowledge and action, various complementary measures were undertaken, which are coordinated in a target manner". However, at least, in the English documents this information was not found.	
13	2. Since tetraplegics do not show classic symptoms of a cardiac infarction, an annual ECG or long-term ECG should be performed from 10 years after the onset of paralysis or if the patient is over 60 years of age.°	3 6	1	1	2	1	l	1	3	3	2,	 *Item 1: The guideline reported a brief introduction for the recommendation. However, the guideline did not describe the evidence to support the recommendation. It is no clear that the consistency of the results (i.e., similarity of results across studies), the directness of the evidence, the precision of the results, the magnitude of the benefits and harms, the likelihood of publication bias, the possibility of confounding factors were analyzed. *Item 2: The guideline addresses a health problem that is relevant to the intended target users and there is an alignment between target user's scope of practice and targeted populations. *Item 3: The recommendation assessed does not include outcomes. Apparently the only outcome was the lifelong follow-up of patients. It is not clear if the guideline evaluated the importance of outcomes to patients. *Item 4: It is not clear that the authors assessed the values and preferences of the guidelines target users. *Item 5: Although the authors mention that patient preferences were taking into account in the REPORT document (Pg 18) there is no information on how this was considered for the recommendation. *Item 7: A clear description of the values and preferences that guideline developers brought to the development process or how values and preferences influenced their interpretation of the balance between benefits and harms is lacking. *Item 8: The guideline recommendation adoption on individuals, organizations, and/or systems are not described. *Item 9: The guideline developers state in the REPORT document (pg 19) that "In order to ensure the transfer of knowledge and action, various complementary measures were undertaken, which are coordinated in a target manner". However, at least, in the English documents this information was not found. 	German speaking society_Lifelong follow-up, 2022 Chapter: 3.3 Cardiovascular diseases Page: 16
14	 10. Nutritional status should be obtained as part of lifelong follow-up for elevated cardiovascular risk factors. With increasing age, also the risk of cardiovascular disease increases. The longer the SCI, the greater the loss of lean mass.^c 	3 6	1	1	2	1	1	1	3	3	2,	 *Item 1: The guideline reported a brief introduction for the recommendation. However, the guideline did not describe the evidence to support the recommendation. It is no clear that the consistency of the results (i.e., similarity of results across studies), the directness of the evidence, the precision of the results, the magnitude of the benefits and harms, the likelihood of publication bias, the possibility of confounding factors were analyzed. *Item 2: The guideline addresses a health problem that is relevant to the intended target users and there is an alignment between target user's scope of practice and targeted populations. *Item 3: The recommendation assessed does not include outcomes. Apparently the only outcome was the lifelong follow-up of patients. It is not clear if the guideline evaluated the importance of outcomes to patients. *Item 4: It is not clear that the authors assessed the values and preferences of the guidelines target users. *Item 5: Although the authors mention that patient preferences were taking into account in the REPORT document (Pg 18) there is no information on how this was considered for the recommendation. *Item 7: A clear description of the values and preferences that guideline developers brought to the development process or how values and preferences influenced their interpretation of the balance between benefits and harms is lacking. *Item 8: The guideline recommendations align with the implementation goals of the guideline. The anticipated impacts of recommendation adoption on individuals, organizations, and/or systems are not described. *Item 9: The guideline developers state in the REPORT document (pg 19) that "In order to ensure the transfer of knowledge and action, various complementary measures were undertaken, which are coordinated in a target manner". However, at least, in the English documents this information was not found. 	German speaking society_Lifelong follow-up, 2022 Chapter: 3.3 Cardiovascular diseases Page: 16

1.7	1 A	b	(1	1	b	4	1	h	b	2	• France 1. TTL - metalling and a ball franching for the state of the	Common angline is title
15	1. As part of lifelong follow-up,	3	6	1	1	2	1	1	3	3	2,	· · · · · · · · · · · · · · · · · · ·	German speaking society_Lifelong
	symptoms of deep vein											not describe the evidence to support the recommendation. It is no clear that the consistency of the results	follow-up, 2022
	thrombosis should be asked											(i.e., similarity of results across studies), the directness of the evidence, the precision of the results, the	Chapter: 3.3 Cardiovascular diseases
	about and clinically examined,											magnitude of the benefits and harms, the likelihood of publication bias, the possibility of confounding	Page: 17
	specifically in the first year after											factors were analyzed.	
	SCI, pregnancy, hormonal											*Item 2: The guideline addresses a health problem that is relevant to the intended target users and there is	
	contraception or in the presence											an alignment between target user's scope of practice and targeted populations.	
	of one of the following risk											*Item 3: The recommendation assessed does not include outcomes. Apparently the only outcome was the	
	factors: smoking, diabetes, age >											lifelong follow-up of patients. It is not clear if the guideline evaluated the importance of outcomes to	
	45 years, AIS A.											patients.	
	For further recommendations on											*Item 4: It is not clear that the authors assessed the values and preferences of the guidelines target users.	
	thromboembolism prophylaxis,											*Item 5: Although the authors mention that patient preferences were taking into account in the REPORT	
	please refer to the AWMF S1											document (Pg 18) there is no information on how this was considered for the recommendation.	
	guideline: "Thromboembolism											*Item 6: It is not clear that the values and preferences of decision/policy makers were directily addressed.	
	prophylaxis in paraplegia".											*Item 7: A clear description of the values and preferences that guideline developers brought to the	
				1								development process or how values and preferences influenced their interpretation of the balance between	
												benefits and harms is lacking.	
												*Item 8: The guideline recommendations align with the implementation goals of the guideline. The	
1				1								anticipated impacts of recommendation adoption on individuals, organizations, and/or systems are not	
												described.	
				1								*Item 9: The guideline developers state in the REPORT document (pg 19) that "In order to ensure the	
												transfer of knowledge and action, various complementary measures were undertaken, which are	
												coordinated in a target manner". However, at least, in the English documents this information was not	
												found.	
16	2. A symptom-based search for	3	6	1	1	2	1	1	3	3	2,		German speaking society_Lifelong
10	respiratory disturbances during	Ĩ	Ŭ	-	-	-	-	1	ĩ	Ĕ	_,	not describe the evidence to support the recommendation. It is no clear that the consistency of the results	follow-up, 2022
	sleep (recommended because of											(i.e., similarity of results across studies), the directness of the evidence, the precision of the results, the	Chapter: 3.4 Respiratory system -
	the frequency of this condition											magnitude of the benefits and harms, the likelihood of publication bias, the possibility of confounding	respiration, ventilation, respiratory
	and its increasing prevalence											factors were analyzed.	infections and sleep-related breathing
	with age) and											*Item 2: The guideline addresses a health problem that is relevant to the intended target users and there is	disorders (b440-b449)
	polygraphy/polysomnography											an alignment between target user's scope of practice and targeted populations.	Page: 17
	should be performed if											*Item 3: The recommendation assessed does not include outcomes. Apparently the only outcome was the	
	suspected.											lifelong follow-up of patients. It is not clear if the guideline evaluated the importance of outcomes to	
												patients.	
												*Item 4: It is not clear that the authors assessed the values and preferences of the guidelines target users.	
												*Item 5: Although the authors mention that patient preferences were taking into account in the REPORT	
												document (Pg 18) there is no information on how this was considered for the recommendation.	
				1								*Item 6: It is not clear that the values and preferences of decision/policy makers were directily addressed.	
				1								*Item 7: A clear description of the values and preferences that guideline developers brought to the	
												development process or how values and preferences influenced their interpretation of the balance between	
				1								benefits and harms is lacking.	
				1								*Item 8: The guideline recommendations align with the implementation goals of the guideline. The	
												anticipated impacts of recommendation adoption on individuals, organizations, and/or systems are not	
												described.	
				1									
				1								*Item 9: The guideline developers state in the REPORT document (pg 19) that "In order to ensure the	
1				1								transfer of knowledge and action, various complementary measures were undertaken, which are	
												coordinated in a target manner". However, at least, in the English documents this information was not	
1.7	1 1 1		_	<u> </u>	-	_			_	<u> </u>	-	found.	
17	1. In the context of lifelong	3	6	μ	1	2	μ	μ	3	3	2,	³ *Item 1: The guideline reported a brief introduction for the recommendation. However, the guideline did	German speaking society_Lifelong
	follow-up, if the basic status is			1								not describe the evidence to support the recommendation. It is no clear that the consistency of the results	follow-up, 2022
	assured (standard vaccinations,			1								(i.e., similarity of results across studies), the directness of the evidence, the precision of the results, the	Chapter: 3.5 Immune system,
	as well as for indication and											magnitude of the benefits and harms, the likelihood of publication bias, the possibility of confounding	vaccinations and allergies (b435)
1	booster vaccinations), the			1								factors were analyzed.	Page: 17
	vaccination status of influenza,	1		1								*Item 2: The guideline addresses a health problem that is relevant to the intended target users and there is	
1													
	,												
	pneumococci, herpes zoster, meningococci, Covid-19 should											an alignment between target user's scope of practice and targeted populations. *Item 3: The recommendation assessed does not include outcomes. Apparently the only outcome was the	

be specifically asked about and, lifelong follow-up of patients. It is not clear if the guideline	evaluated the importance of outcomes to
if necessary, recommended.	
*Item 4: It is not clear that the authors assessed the values and	
*Item 5: Although the authors mention that patient preference	
document (Pg 18) there is no information on how this was c	nsidered for the recommendation.
*Item 6: It is not clear that the values and preferences of dec	sion/policy makers were directily addressed.
*Item 7: A clear description of the values and preferences the	at guideline developers brought to the
development process or how values and preferences influence	
benefits and harms is lacking.	
*Item 8: The guideline recommendations align with the imp	ementation goals of the guideline. The
anticipated impacts of recommendation adoption on individu	
	ais, organizations, and/or systems are not
described.	
*Item 9: The guideline developers state in the REPORT doc	
transfer of knowledge and action, various complementary m	
coordinated in a target manner". However, at least, in the En	glish documents this information was not
found.	
18 1. Colonoscopy shall be 3 6 1 1 2 1 1 3 3 2,3 *Item 1: The guideline reported a brief introduction for the	ecommendation. However, the guideline did German speaking society_Lifelong
performed similar to the general not describe the evidence to support the recommendation. It	
population according to (i.e., similarity of results across studies), the directness of th	
guidelines set by professional magnitude of the benefits and harms, the likelihood of publi	
societies (recommended at age	Paragraph: 1
50 years, with a follow-up * Item 2: The guideline addresses a health problem that is rel	
examination every 10 years	
thereafter, or earlier depending *Item 3: The recommendation assessed does not include out	
on findings) ^e lifelong follow-up of patients. It is not clear if the guideline	evaluated the importance of outcomes to
patients.	
*Item 4: It is not clear that the authors assessed the values and	
*Item 5: Although the authors mention that patient preference	
document (Pg 18) there is no information on how this was c	
*Item 6: It is not clear that the values and preferences of dec	sion/policy makers were directily addressed.
*Item 7: A clear description of the values and preferences the	at guideline developers brought to the
development process or how values and preferences influence	ed their interpretation of the balance between
benefits and harms is lacking.	*
*Item 8: The guideline recommendations align with the imp	ementation goals of the guideline. The
anticipated impacts of recommendation adoption on individ	
described.	,
*Item 9: The guideline developers state in the REPORT doc	iment (ng 10) that "In order to ensure the
transfer of knowledge and action, various complementary m	
coordinated in a target manner". However, at least, in the Er	gish documents this information was not
19 1. As part of lifelong follow-up, 3 6 1 1 2 1 1 3 3 2,3 *Item 1: The guideline reported a brief introduction for the	
all individuals with SCI should not describe the evidence to support the recommendation. It	
have regular/annual evaluations (i.e., similarity of results across studies), the directness of th	
for possible upper extremity magnitude of the benefits and harms, the likelihood of public	ation bias, the possibility of confounding Page: 31
problems (especially shoulder, factors were analyzed.	
elbow, wrist, and carpal tunnel *Item 2: The guideline addresses a health problem that is rei	
syndrome). ^c an alignment between target user's scope of practice and tar	eted populations.
*Item 3: The recommendation assessed does not include out	
2. It is therefore advisable to lifelong follow-up of patients. It is not clear if the guideline	
carry out the checks on all patients.	1
patients, but to pay particular * Item 4: It is not clear that the authors assessed the values at	d preferences of the guidelines target users
attention to elderly people and * Item 5: Although the authors mention that patient preference	es were taking into account in the REPORT
those who have been in a document (Pg 18) there is no information on how this was c	
wheelchair for a long time. ^c *Item 6: It is not clear that the values and preferences of dec	
*Item 7: A clear description of the values and preferences the	
development process or how values and preferences influences	ed their interpretation of the balance between

											benefits and harms is lacking. *Item 8: The guideline recommendations align with the implementation goals of the guideline. The anticipated impacts of recommendation adoption on individuals, organizations, and/or systems are not described. *Item 9: The guideline developers state in the REPORT document (pg 19) that "In order to ensure the transfer of knowledge and action, various complementary measures were undertaken, which are coordinated in a target manner". However, at least, in the English documents this information was not found.			
20	Clinicians should discuss with the individual with SCI, family members and caregivers that there may be an increased risk of bladder cancer in individuals with neurogenic lower urinary tract dysfunction, particularly in those with a long history of neurogenic lower urinary tract dysfunction and complicating factors, such as recurrent urinary tract infections. Clinicians should educate individuals with SCI regarding the symptoms to look out for (for example, recurrent infection, recurrent catheter blockages, or hematuria), which mean they should see a healthcare professional. ^e Educate women with SCI about the effects of perimenopausal and menopausal changes on sexual function, bone health, accelerated metabolic aging, and metabolic syndrome after SCI.	3 6 3 6	1	1	1	1	1		3	2,2	 *Item 1: The guideline adopted the recommendation from the 2012 NICE guideline for Urinary incontinence in neurological disease. However there is no analysis on the specific evidence to support the recommendation. *Item 2: The guideline addresses a health problem that is relevant to the intended target users and there is an alignment between target user's scope of practice and targeted populations. *Item 3: The recommendation assessed does not include outcomes. It is not clear if the guideline evaluated the importance of outcomes to patients. *Item 4: It is not clear that the authors assessed the values and preferences of the guidelines target users. *Item 5: It is not clear that the values and preferences of decision/policy makers were directily addressed. *Item 7: A clear description of the values and preferences that guideline developers brought to the development process or how values and preferences influenced their interpretation of the balance between benefits and harms is lacking. *Item 8: The guideline recommendation adoption on individuals, organizations, and/or systems are not described. *Item 9: The guideline website has links to suggested online resources and tools identified by the Expert Panel members. However, it is not clear that the guideline describes the degree of change required from current practice or articulates relevant factors important to its successful dissemination. 	Can-SCIP, Chapter: R. relationships Section: R12.	Sexual	K.16.1
22	3.1 In SCI patients, higher doses	4 6	6	1	1	1	2	7	6	3,8	 *Item 5: It is not clear that the values and preferences of the patients were sought or considered. *Item 6: It is not clear that the values and preferences of decision/policy makers were directily addressed. *Item 7: A clear description of the values and preferences that guideline developers brought to the development process or how values and preferences influenced their interpretation of the balance between benefits and harms is lacking. *Item 8: The guideline recommendations align with the implementation goals of the guideline. The anticipated impacts of recommendation adoption on individuals, organizations, and/or systems are not described. *Item 9: The guideline website has links to suggested online resources and tools identified by the Expert Panel members. However, it is not clear that the guideline describes the degree of change required from current practice or articulates relevant factors important to its successful dissemination. *Item 1: In general, they have a good review of the quality and results of the available evidence, not 	Sekido N_Ur		
	might be required to improve detrusor overactivity and/or bladder compliance, which means that adverse anticholinergic events, such as dry mouth, constipation and blurred vision, might be more problematic. In addition, especially in elderly patients, the										describes the consistency of the results. *Item 2: The recommendations address a health problem that is relevant to the intended target users. Also there is an alignment between target user's scope of practice and targeted patients *Item 3: The guideline includes outcomes that are relevant to the targeted patients/populations. Also this recommendation describes how to tailor recommendations for application to individual patients or populations (e.g., based on age). *Item 4: It is not clear that they directly assess the values and preferences of the guide's target users. *Item 5: The values and preferences of the target population have not been sought or considered. *Item 6: The values and preferences of decision/policy makers are not addressed.	Chapter: 3. F Page: 283	harmacologi	cal therapy

		1 1			-	-						1
	total anticholinergic load should										*Item 7: It is not clear the opinion of the guideline developers.	
	be taken into account to prevent										*Item 8: This recommendation is aligned with the implementation goals of the guideline	
	cognitive impairment.									:	*Item 9: It is not clear that the recommendation assessed the setting, and/or the health system in which	
										1	they are being implemented. They say about this recommendation are not expected to have a significant	
	Eventually, the panel concluded										resource impact or be difficult to implement.	
	that anticholinergic drugs are										······································	
	recommended for patients who											
	have the risk factors for renal											
	damage and symptomatic											
	urinary tract infection or urinary											
	incontinence.							\rightarrow				
23	4.3 Individuals with SCI should	57	7	7	1	7	6	7 -	55		*Item 1: In general, they have a good review of the quality and results of the available evidence, however	
	not be uniformly placed on high-										placebo-controlled trials regarding both dietary fiber and fiber supplementation are lacking in the SCI	Chapter: 4. Diet, supplements, fiber,
	fiber diets. Increases in fiber									1	population.	fluids, and probiotics
	intake from food or a										*Item 2: The recommendations address a health problem that is relevant to the intended target users. Also	Page: 27
	supplement should be done										there is an alignment between target user's scope of practice and targeted patients	C
	gradually to assess tolerance.										*Item 3: The guideline includes outcomes that are relevant to the targeted patients/populations. for	
	gradually to assess toterallee.										example among the relevant outcomes is the relief of constipation.	
	Daily Eihan Quartity											
1	Daily Fiber Quantity			1	1		1				*Item 4: It is clear that they directly assess the values and preferences of the guide's target users such as	
1	Recommendations: Adequate			1	1		1				health carers.	
1	intake for daily recommended			1	1	1	1				*Item 5: The values and preferences of the target population have not been sought or considered.	
1	fiber is 25 g for women and 38 g			1	1	1	1				*Item 6: The values and preferences of decision/policy makers are addressed such as associations and	
	for men under 50 years of age.										consortiums	
	To account for decreased food									:	*Item 7: It is clear the values of the guideline developers.	
	intake with aging, for men and									:	*Item 8: This recommendation is aligned with the implementation goals of the guideline	
	women over 50 the daily										*Item 9: the recommendation assessed the setting which they are being implemented.	
	recommended amount is 21 g for											
	women and 30 g for men.											
24	5.1 Providers can use oral	3 7	7	7	1	7	7	6 5	5 5	5.6	*Item 1: The evidence for their use is limited and there are no data to suggest the use of one medication	Consortium_Neurogenic bowel, 2020
24		5 /	/	'	1	<i>'</i>	<i>'</i>	0 2	5 5			
	medications for bowel										over another. Also they say that Multiple studies in the non-SCI population show good efficacy of osmotic	
	management; however, the										and stimulant laxatives in treating constipation.	Page: 30
	evidence for their use is limited										*Item 2: The recommendations address a health problem that is relevant to the intended target users. Also	
	and there are no data to suggest										there is an alignment between target user's scope of practice and targeted patients	
	the use of one medication over									:	*Item 3: The guideline includes outcomes that are relevant to the targeted patients/populations.	
	another.									:	*Item 4: It is clear that they directly assess the values and preferences of the guide's target users	
											*Item 5: The values and preferences of the target population have not been sought or considered.	
	The standard dose of										*Item 6: The values and preferences of decision/policy makers are addressed such as associations and	
1	prucalopride is 2 mg, but in			1	1		1				consortiums	
1	individuals older than 60 years,			1	1		1				*Item 7: It is clear the values of the guideline developers.	
	the dose is usually 1 mg daily.										*Item 8: This recommendation is aligned with the implementation goals of the guideline	
1	the dose is usually 1 llig daily.			1	1	1	1					
							1				*Item 9: the recommendation assessed the setting which they are being implemented.	
0.5		4		-	1	-	-		- 1-			
25	6.4 The routine use of enema	46	7	7	1	7	2	65	55		*Item 1: It is need more evidence, Expert opinion does not generally support the use of phosphate enemas	Consortium_Neurogenic bowel, 2020
25	formulations such as sodium	46	7	7	1	7	2	6	5 5		(such as Fleet) for individuals with SCI for bowel management.	Chapter: 6. Use of suppositories,
25	formulations such as sodium phosphate (Phospho-Soda),	46	7	7	1	7	2	6	5 5		(such as Fleet) for individuals with SCI for bowel management. *Item 2: The recommendations address a health problem that is relevant to the intended target users. Also	Chapter: 6. Use of suppositories, enemas, and irrigation
25	formulations such as sodium	46	7	7	1	7	2	6	5 5	1	(such as Fleet) for individuals with SCI for bowel management. *Item 2: The recommendations address a health problem that is relevant to the intended target users. Also there is an alignment between target user's scope of practice and targeted patients	Chapter: 6. Use of suppositories,
25	formulations such as sodium phosphate (Phospho-Soda),	46	7	7	1	7	2	6	5 5	1	(such as Fleet) for individuals with SCI for bowel management. *Item 2: The recommendations address a health problem that is relevant to the intended target users. Also	Chapter: 6. Use of suppositories, enemas, and irrigation
25	formulations such as sodium phosphate (Phospho-Soda), soapsuds, or milk and molasses	46	7	7	1	7	2	6	5 5	1	(such as Fleet) for individuals with SCI for bowel management. *Item 2: The recommendations address a health problem that is relevant to the intended target users. Also there is an alignment between target user's scope of practice and targeted patients *Item 3: The guideline includes outcomes that are relevant to the targeted patients/populations.	Chapter: 6. Use of suppositories, enemas, and irrigation
25	formulations such as sodium phosphate (Phospho-Soda), soapsuds, or milk and molasses is not recommended; however, in selected individuals,	46	7	7	1	7	2	6	5 5	1	(such as Fleet) for individuals with SCI for bowel management. *Item 2: The recommendations address a health problem that is relevant to the intended target users. Also there is an alignment between target user's scope of practice and targeted patients *Item 3: The guideline includes outcomes that are relevant to the targeted patients/populations. *Item 4: It is clear that they directly assess the values and preferences of the guide's target users	Chapter: 6. Use of suppositories, enemas, and irrigation
25	formulations such as sodium phosphate (Phospho-Soda), soapsuds, or milk and molasses is not recommended; however, in selected individuals, intermittent use for constipation	4 6	7	7	1	7	2	6	5 5	1	(such as Fleet) for individuals with SCI for bowel management. *Item 2: The recommendations address a health problem that is relevant to the intended target users. Also there is an alignment between target user's scope of practice and targeted patients *Item 3: The guideline includes outcomes that are relevant to the targeted patients/populations. *Item 4: It is clear that they directly assess the values and preferences of the guide's target users *Item 5: The values and preferences of the target population have not been sought or considered.	Chapter: 6. Use of suppositories, enemas, and irrigation
25	formulations such as sodium phosphate (Phospho-Soda), soapsuds, or milk and molasses is not recommended; however, in selected individuals,	4 6	7	7	1	7	2	6	5 5	1	(such as Fleet) for individuals with SCI for bowel management. *Item 2: The recommendations address a health problem that is relevant to the intended target users. Also there is an alignment between target user's scope of practice and targeted patients *Item 3: The guideline includes outcomes that are relevant to the targeted patients/populations. *Item 4: It is clear that they directly assess the values and preferences of the guide's target users *Item 5: The values and preferences of the target population have not been sought or considered. *Item 6: The values and preferences of decision/policy makers are addressed such as FDA.	Chapter: 6. Use of suppositories, enemas, and irrigation
25	formulations such as sodium phosphate (Phospho-Soda), soapsuds, or milk and molasses is not recommended; however, in selected individuals, intermittent use for constipation may be helpful.	4 6	7	7	1	7	2	6	5 5	1	(such as Fleet) for individuals with SCI for bowel management. *Item 2: The recommendations address a health problem that is relevant to the intended target users. Also there is an alignment between target user's scope of practice and targeted patients *Item 3: The guideline includes outcomes that are relevant to the targeted patients/populations. *Item 4: It is clear that they directly assess the values and preferences of the guide's target users *Item 5: The values and preferences of the target population have not been sought or considered. *Item 6: The values and preferences of decision/policy makers are addressed such as FDA. *Item 7: It is not clear the values of the guideline developers.	Chapter: 6. Use of suppositories, enemas, and irrigation
25	formulations such as sodium phosphate (Phospho-Soda), soapsuds, or milk and molasses is not recommended; however, in selected individuals, intermittent use for constipation may be helpful. In 2014, the FDA released a	4 6	7	7	1	7	2	6	5 5	- - - - - - - - - - - - - - - - - - -	 (such as Fleet) for individuals with SCI for bowel management. *Item 2: The recommendations address a health problem that is relevant to the intended target users. Also there is an alignment between target user's scope of practice and targeted patients *Item 3: The guideline includes outcomes that are relevant to the targeted patients/populations. *Item 4: It is clear that they directly assess the values and preferences of the guide's target users *Item 5: The values and preferences of the target population have not been sought or considered. *Item 6: The values and preferences of the guideline developers. *Item 8: This recommendation is aligned with the implementation goals of the guideline 	Chapter: 6. Use of suppositories, enemas, and irrigation
25	formulations such as sodium phosphate (Phospho-Soda), soapsuds, or milk and molasses is not recommended; however, in selected individuals, intermittent use for constipation may be helpful. In 2014, the FDA released a warning that physicians should	4 6	7	7	1	7	2	6	5 5	- - - - - - - - - - - - - - - - - - -	(such as Fleet) for individuals with SCI for bowel management. *Item 2: The recommendations address a health problem that is relevant to the intended target users. Also there is an alignment between target user's scope of practice and targeted patients *Item 3: The guideline includes outcomes that are relevant to the targeted patients/populations. *Item 4: It is clear that they directly assess the values and preferences of the guide's target users *Item 5: The values and preferences of the target population have not been sought or considered. *Item 6: The values and preferences of decision/policy makers are addressed such as FDA. *Item 7: It is not clear the values of the guideline developers.	Chapter: 6. Use of suppositories, enemas, and irrigation
25	formulations such as sodium phosphate (Phospho-Soda), soapsuds, or milk and molasses is not recommended; however, in selected individuals, intermittent use for constipation may be helpful. In 2014, the FDA released a warning that physicians should be consulted prior to the use of	4 6	7	7	1	7	2	6	5 5	- - - - - - - - - - - - - - - - - - -	 (such as Fleet) for individuals with SCI for bowel management. *Item 2: The recommendations address a health problem that is relevant to the intended target users. Also there is an alignment between target user's scope of practice and targeted patients *Item 3: The guideline includes outcomes that are relevant to the targeted patients/populations. *Item 4: It is clear that they directly assess the values and preferences of the guide's target users *Item 5: The values and preferences of the target population have not been sought or considered. *Item 6: The values and preferences of the guideline developers. *Item 8: This recommendation is aligned with the implementation goals of the guideline 	Chapter: 6. Use of suppositories, enemas, and irrigation
25	formulations such as sodium phosphate (Phospho-Soda), soapsuds, or milk and molasses is not recommended; however, in selected individuals, intermittent use for constipation may be helpful. In 2014, the FDA released a warning that physicians should be consulted prior to the use of sodium phosphate enemas for	4 6	7	7	1	7	2	6	5 5	- - - - - - - - - - - - - - - - - - -	 (such as Fleet) for individuals with SCI for bowel management. *Item 2: The recommendations address a health problem that is relevant to the intended target users. Also there is an alignment between target user's scope of practice and targeted patients *Item 3: The guideline includes outcomes that are relevant to the targeted patients/populations. *Item 4: It is clear that they directly assess the values and preferences of the guide's target users *Item 5: The values and preferences of the target population have not been sought or considered. *Item 6: The values and preferences of the guideline developers. *Item 8: This recommendation is aligned with the implementation goals of the guideline 	Chapter: 6. Use of suppositories, enemas, and irrigation
25	formulations such as sodium phosphate (Phospho-Soda), soapsuds, or milk and molasses is not recommended; however, in selected individuals, intermittent use for constipation may be helpful. In 2014, the FDA released a warning that physicians should be consulted prior to the use of	4 6	7	7	1	7	2	6	5 5	- - - - - - - - - - - - - - - - - - -	 (such as Fleet) for individuals with SCI for bowel management. *Item 2: The recommendations address a health problem that is relevant to the intended target users. Also there is an alignment between target user's scope of practice and targeted patients *Item 3: The guideline includes outcomes that are relevant to the targeted patients/populations. *Item 4: It is clear that they directly assess the values and preferences of the guide's target users *Item 5: The values and preferences of the target population have not been sought or considered. *Item 6: The values and preferences of the guideline developers. *Item 8: This recommendation is aligned with the implementation goals of the guideline 	Chapter: 6. Use of suppositories, enemas, and irrigation
25	formulations such as sodium phosphate (Phospho-Soda), soapsuds, or milk and molasses is not recommended; however, in selected individuals, intermittent use for constipation may be helpful. In 2014, the FDA released a warning that physicians should be consulted prior to the use of sodium phosphate enemas for	4 6	7	7	1	7	2	6	5 5	- - - - - - - - - - - - - - - - - - -	 (such as Fleet) for individuals with SCI for bowel management. *Item 2: The recommendations address a health problem that is relevant to the intended target users. Also there is an alignment between target user's scope of practice and targeted patients *Item 3: The guideline includes outcomes that are relevant to the targeted patients/populations. *Item 4: It is clear that they directly assess the values and preferences of the guide's target users *Item 5: The values and preferences of the target population have not been sought or considered. *Item 6: The values and preferences of the guideline developers. *Item 8: This recommendation is aligned with the implementation goals of the guideline 	Chapter: 6. Use of suppositories, enemas, and irrigation

26	 2.20 If there is history of difficulty passing a catheter in a male, consider using a coudé catheter or consult urology. A coudé catheter is especially useful in those with a history of sphincterotomy and in older men, in particular those with a history of prostatic hypertrophy or transurethral resection of the prostate. 31. At present orlistat is the only licenced medication for the treatment of obesity. It is associated with increased rates of gastrointestinal events. This could include steatorrhea, fatty faecal incontinence or urgency of bowel movements. This 	6 7 7 7	7	6	1	1	7	7 3		 *Item 1: In general, they have a good review of the quality and results of the available evidence and this recommendation has a better quality review specially in old people. *Item 2: The recommendations address a health problem that is relevant to the intended target users. Also there is an alignment between target user's scope of practice and targeted patients. For example they say that this recommendation is better in older men, in particular those with a history of prostatic hypertrophy or transurethral resection of the prostate. *Item 3: The guideline includes outcomes that are relevant to the targeted patients/populations. for example among the relevant outcomes is less trauma. *Item 4: It is clear that they directly assess the values and preferences of the guide's target users. *Item 6: The values and preferences of the target population have not been sought or considered. *Item 9: It is clear that values of the guideline developers. *Item 9: it is not clear that recommendation assessed the setting which they are being implemented. *Item 1:They have a strong consensus, they have a good review of the quality and results of the available evidence *Item 3: The guideline includes outcomes that are relevant to the intended target users. Also there is an alignment between target user's scope of practice and targeted patients. 	Page: 23 MASCIP_W	utonomic eight manag fedical an	dysreflexia, Dysreflexia ement, 2019 d Surgical
	impact of these medications should be considered in the context of bowel management. These effects can be reduced by adhering to a low-fat diet and distributing daily fat intake over three main meals. A multivitamin and mineral supplement may be considered whilst using this medication. If there is concern about micronutrient intake adequacy, a supplement providing the reference nutrient intake for all vitamins and minerals should be considered, particularly for yulnerable groups such as older									 The values and preferences of the taget population have not overhous of considered for example inquire for the adverse affects. *Item 6: The values and preferences of decision/policy makers are not addressed . *Item 7: It is clear the values of the guideline developers. *Item 8: This recommendation is aligned with the implementation goals of the guideline *Item 9: it is clear that recommendation assessed the setting which they are being implemented. Also to the context, they explain that when using this medication one should consider using a multivitamin and mineral supplement. Also they explain that taking the medication need to be aware. These factors are of importance in the context of bowel management for people with a SCI. 			
28	people and young people. 6.7 Postanal repair results in satisfactory outcome in the long term in patients with neurogenic sphincter weakness. However, this is a single center experience, which needs further confirmation. Postanal repair () is useful in the elderly or those with significant co-morbidities.	3 3	1	1	1	1	1	1 1		 *Item 1: The guideline is an update of the recommendations from the 4th International Consultations on Incontinence (2009) for the clinical management of neurogenic bowel dysfunction. The assessed recommendation is based in a single study. It does not describe the directness of the evidence, the precision of the results, the magnitude of the benefits and harms, the likelihood of publication bias, the possibility of confounding factors. *Item 2: The guideline addresses a health problem that is relevant to the intended target users. There is no detailed information on the target user's scope of practice, the targeted populations, or the trade-offs between harms and benefits. *Item 3: The recommendation does not specify the outcome that was taken into account. It is not clear if the guideline evaluated the importance of outcomes to patients. *Item 4: It is not clear that the authors assessed the values and preferences of the guidelines target users. *Item 5: It is not clear that the values and preferences of the patients were sought or considered. *Item 7: A clear description of the values and preferences influenced their interpretation of the balance between 	International Incontinence Chapter: Page: 52	Consult Surgical	ation on 2018 treatment

29	35. It is recommended that Physical and Rehabilitation Medicine (PRM) physicians continue long-term follow-up of persons with SCI, also when ageing, aiming to meet the individualised needs of the person using diverse treatment strategies along the lifespan of these persons with a life-long disability (see also Evidence- Based Position Paper (EBPP) ^f for ageing persons with disabilities).	2 3	1	1	1	1	1	1	1	1,3	 benefits and harms is lacking. *Item 8: The implementation goals of the guideline, the anticipated impacts of recommendation adoption on individuals, organizations, and/or systems are not described. *Item 9: The guideline does not mention any information for the implementation of the recommendation It is not clear that the guideline describes the degree of change required from current practice or articular relevant factors important to its successful dissemination. *Item 1: The authors of the Evidence-based position paper did not formulate single questions to make the recommendation was based on three references. However, the authors did not describe the consistency of precision of the results, the directness of the evidence, the magnitude of the benefits and harms, the likelihood of publication bias, the possibility of confounding factors. *Item 2: The evidence-based position paper addresses a health problem that is relevant. However there i no clear description of to the intended target users, scope of practice or targeted populations. *Item 3: The recommendation assessed does not include outcomes (It's a general recommendation for the long term follow up of PRM specialists to SCI patients). It is not clear that the authors assessed the values and preferences of the guidelines target users. *Item 4: It is not clear that the authors assessed the values and preferences of the guidelines target users. *Item 7: A clear description of the values and preferences of decision/policy makers were directily addressed *Item 7: A clear description of the values and preferences influence duelopers brought to the development process or how values and preferences influence their interpretation goals. The anticipated impacts of recommendation adoption on individuals, organizations, and/or systems are not described. *Item 8: The evidence-based position paper does not include any implementation goals. The anticipated impacts of recommendation adopt	s UEMS_PRM, 2018 r Chapter: D. Recommendations on PRM management and process Page: 804
30	 3.2.3 Special care should be taken of patients at risk for autonomic dysreflexia (mainly patients with SCI above T6), being aware of the clinical signs of the onset of the crisis (eg, head sweating, headache) and its management (stop the filling, tilting the table, nifedipine). Moreover, blood pressure assessment during the urodynamic study is advisable. Considering the high incidence of silent episodes of autonomic dysreflexia during the urodynamic, they recommended that monitoring of cardiovascular parameters during these procedures be routinely performed. The authors strongly recommended blood pressure monitoring during urodynamic especially for elderly SCI patients. Evidence-based guidelines for for the strong second secon	2 3	1	1	1	1	1	1		1,3	 *Item 1: The best practice paper reported a rationale for the recommendation. The authors did not formulate single questions to make the recommendations. After the review of the literature the recommendations were formulated. This particular recommendation was based on three references. However, the authors did not describe the consistency or precision of the results, the directness of the evidence, the magnitude of the benefits and harms, the likelihood of publication bias, the possibility of confounding factors. *Item 2: The best practice paper addresses a health problem that is relevant to the intended target users a there is an alignment between target user's scope of practice and targeted populations. *Item 3: The recommendation assessed does not include outcomes (It's a general recommendation for bone density testing). Also, the best practice paper does not report how the importance of outcomes to patients was determined. *Item 4: It is not clear that the authors assessed the values and preferences of the guidelines target users. *Item 6: It is not clear that the values and preferences of the patients were sought or considered. *Item 6: It is not clear that the values and preferences of the guideline developers brought to the development process or how values and preferences influenced their interpretation of the balance between benefits and harms is lacking. *Item 8: The best practice paper does not include any implementation goals. The anticipated impacts of recommendation adoption on individuals, organizations, and/or systems are not described. *Item 9: The evidence-based position paper does not mention any information for the implementation or the recommendation. It is not clear that the guideline describes the degree of change required from curre practice or articulates relevant factors important to its successful dissemination. 	1
51	treating hypertension in the	ſ	Ť	-	1	Ť	1	1	Ĺ	 ,0	guideline did not describe the consistency or precision of the results, the directness of the evidence, the	2018

	1 1.4 1 111	T			1	-	1		1	-				C
	eneral population should be											magnitude of the benefits and harms, the likelihood of publication bias or the possibility of confounding	Chapter: Pharmacotherapy	for
	sed to treat individuals with CI. For most adults, a threshold											factors. *It	Hypertension	
	· · · · · · · · · · · · · · · · · · ·											*Item 2: The guideline addresses a health problem that is relevant. However there is no clear description of	Page: 28	
	or initiating pharmacological											to the intended target users, scope of practice or targeted populations.		
	eatment and treatment target of											*Item 3: The recommendation assessed does not include outcomes (It's a general recommendation for		
	40/90 mm Hg is reasonable,											pharmacotherapy for hypertension). Also, the guideline does not report if the importance of outcomes to		
	Ithough different targets may be											patients was sought.		
	onsidered in certain individuals											*Item 4: It is not clear that the authors assessed the values and preferences of the guidelines target users.		
ar	nd sub-populations.											*Item 5: It is not clear that the values and preferences of the patients were sought or considered.		
												*Item 6: It is not clear that the values and preferences of decision/policy makers were directily addressed.		
) The Eighth Joint National											*Item 7: A clear description of the values and preferences that guideline developers brought to the		
С	committee (JNC 8) evidence-											development process or how values and preferences influenced their interpretation of the balance between		
ba	ased guideline for the											benefits and harms is lacking.		
m	nanagement of high blood											*Item 8: The guideline does not include any implementation goals. The anticipated impacts of		
pi	ressure in adults recommends											recommendation adoption on individuals, organizations, and/or systems are not described.		
in	nitiating pharmacological											*Item 9: The guideline does not mention any information for the implementation of the recommendation.		
	reatment to lower blood											It is not clear that the guideline describes the degree of change required from current practice or articulates		
	ressure at systolic blood											relevant factors important to its successful dissemination.		
	ressure of 150 mm Hg or higher													
	r diastolic blood pressure of 90													
	nm Hg or higher in adults age													
	0 or higher without diabetes or													
	hronic kidney disease.1													
	7	3 4	L	1	1	1	1	1	1	1	1,6	*Item 1: The guideline reported a rationale for the recommendation, based on evidence. However, the	Consortium_Cardiometabolic	risk,
	when selecting an			•	1	1	1	-	1	1	1,0	guideline did not describe the consistency or precision of the results, the directness of the evidence, the	2018	115K,
	ntihypertensive agent, such as											magnitude of the benefits and harms, the likelihood of publication bias or the possibility of confounding		for
ai th	ne effect of thiazide diuretics on											factors.	Chapter: Pharmacotherapy Hypertension	101
	ladder management.											*Item 2: The guideline addresses a health problem that is relevant. However there is no clear description of		
01	laddel management.												rage. 28	
(to the intended target users, scope of practice or targeted populations.		
)Hyponatremia, hypokalemia,											*Item 3: The recommendation assessed does not include outcomes (It's a general recommendation for		
	r decline in renal function											pharmacotherapy for hypertension). Also, the guideline does not report if the importance of outcomes to		
	ometimes occur during the first											patients was sought.		
	ine months of thiazide use, and											*Item 4: It is not clear that the authors assessed the values and preferences of the guidelines target users.		
	lder patients may be especially											*Item 5: It is not clear that the values and preferences of the patients were sought or considered.		
	ulnerable to renal electrolyte											*Item 6: It is not clear that the values and preferences of decision/policy makers were directily addressed.		
	isturbances, gout,											*Item 7: A clear description of the values and preferences that guideline developers brought to the		
hy	yperglycemia, and hypotension.											development process or how values and preferences influenced their interpretation of the balance between		
												benefits and harms is lacking.		
												*Item 8: The guideline does not include any implementation goals. The anticipated impacts of		
												recommendation adoption on individuals, organizations, and/or systems are not described.		
												*Item 9: The guideline does not mention any information for the implementation of the recommendation.		
												It is not clear that the guideline describes the degree of change required from current practice or articulates		
												relevant factors important to its successful dissemination.		
33 7.	.0 We recommend that	34	Ļ	1	1	1	1	1	1	1	1,6	*Item 1: The guideline reported a rationale for the recommendation, based on evidence. However, the	Consortium_Venous	
	nticoagulant											guideline did not describe the consistency or precision of the results, the directness of the evidence, the	thromboembolism,	2016
	romboprophylaxis continue at											magnitude of the benefits and harms, the likelihood of publication bias or the possibility of confounding	Chapter: Duration	of
	east eight weeks after injury in											factors.	Thromboprophylaxis	
	CI patients with limited											*Item 2: The guideline addresses a health problem that is relevant. However there is no clear description of		
	nobility.											to the intended target users, scope of practice or targeted populations.	1 ugo. 10	
	loomity.											*Item 3: The recommendation assessed does not include outcomes (It's a general recommendation for the		
т	he specific duration should be											duration of thromboprophylaxis). Also, the guideline does not report if the importance of outcomes to		
	ndividualised for each patient,											patients was sought.		
	king into consideration the											*Item 4: It is not clear that the authors assessed the values and preferences of the guidelines target users.		
	evel and completeness of the											*Item 5: It is not clear that the values and preferences of the patients were sought or considered.		
	eurological injury, concomitant											*Item 6: It is not clear that the values and preferences of decision/policy makers were directily addressed.		
in	njuries and medical conditions,											*Item 7: A clear description of the values and preferences that guideline developers brought to the		

bleeding risk, functional status, and feasibility. Factors suggesting longer duration of thromboprophylaxis include motor complete injuries, lower- extremity fractures, older age, previous venous thromboembolism, cancer, and obesity.			development process or how values and preferences influenced their interpretation of the balance between benefits and harms is lacking. *Item 8: The guideline does not include any implementation goals. The anticipated impacts of recommendation adoption on individuals, organizations, and/or systems are not described. *Item 9: The guideline does not mention any information for the implementation of the recommendation. It is not clear that the guideline describes the degree of change required from current practice or articulates relevant factors important to its successful dissemination.
 34 1. Conduct an assessment of pressure ulcer risk factors in individuals with SCI at every appropriate opportunity. Assess the following risk factors for the development of pressure ulcers: Demographic (age) SCI-related, such as incontinence Comorbid medical Nutritional Psychological, cognitive, contextual, and social Support surface for bed, wheelchair, and all durable medical equipment (DME) surface such as shower/commode chair or bathroom equipment related. Use both a validated risk-assessment tool and clinical judgment to assess risk. 	4 1 1		 1.6 *Item 1: The guideline reported a rationale for the recommendation, based on evidence. However, the guideline did not describe the consistency or precision of the results, the directness of the evidence, the magnitude of the benefits and harms, the likelihood of publication bias or the possibility of confounding factors. *Item 2: The guideline addresses a health problem that is relevant. However there is no clear description of to the intended target users, scope of practice or targeted populations. *Item 3: The recommendation assessed does not include outcomes (It's a general recommendation for the risk for the development of pressure ulcers.). Also, the guideline does not report if the importance of outcomes to patients was sought. *Item 4: It is not clear that the authors assessed the values and preferences of the guideline starget users. *Item 5: It is not clear that the values and preferences of decision/policy makers were directily addressed. *Item 7: A clear description of the values and preferences influenced their interpretation of the balance between benefits and harms is lacking. *Item 8: The guideline does not include any implementation goals. The anticipated impacts of recommendation. It is not clear that the guideline describes the degree of change required from current practice or articulates relevant factors important to its successful dissemination.
 4.2: 24-hour approach to pressure ulcer risk management Perform a comprehensive assessment of posture and positioning to evaluate pressure ulcer risk. Consider all surfaces in both recumbent and sitting positions that a person uses to participate in daily activities over the entire 24-hour period. () Long-term spinal cord injury phase: The risk of pressure ulcers may increase over time due to changes in function, strength, and mobility that typically occur with increasing duration of spinal cord injury and with aging. Physical changes increase pressure ulcer risk and may require more intensive pressure ulcer management practices. 	4 5 1	4 1 1 5 1	 2.7 *Item 1: there is not a review of the quality and results of the available evidence. They were based on the Consortium for Spinal Cord Medicine Clinical Practice Guidelines. The recommendation don't assess any risk of bias related to the study designs of the supporting evidence, not describes the consistency of the results. *Item 2: The recommendations address a health problem that is relevant to the intended target users. Also there is an alignment between target user's scope of practice and targeted patients *Item 3: The outcomes that are relevant to the targeted patients/populations are not clear enough. but this recommendation describes some important points *Item 4: It is not clear that they directly assess the values and preferences of the directly.guide's target users. *Item 5: The values and preferences of the target population have not been sought or considered. However they recommend to understanding the individual: The clinician gathers information during the assessment to understand the person, relevant issues, goals, functional abilities, lifestyle, and specific needs. *Item 6: The values and preferences of decision/policy makers are not addressed. *Item 7: Not adressed. They were based on the Consortium for Spinal Cord Medicine Clinical Practice Guidelines. Pressure ulcer provention and treatment following spinal cord injury: a clinical practice guideline for health-care professionals. *Item 8: This recommendation is aligned with the implementation goals of the guideline *Item 9: It is not clear that the recommendation assessed the setting, and/or the health system in which they are being implemented

26	4.5. Decococoment	1	4	4	1	Н	1	1	1	5	1	2 1	*Item 1. they did not mention the course of the recommendation there is not a review of the quality and	Considion Drossums	ulaama 20
	 4.5: Reassessment Reassess pressure management using a 24-hour approach every 2 years, or more often if a pressure ulcer develops or there is a significant change in health status — including weight changes or functional ability — or if there are changes in living situation or a deterioration in the support surface/equipment. () Reassessment can achieve the following: Identify the impact of physical changes due to aging and increasing duration of spinal cord injury, including postural changes, muscle wasting, and 	1	4	4	1	Ľ		1	1	5	1	2,1	 *Item 1: they did not mention the source of the recommendation. there is not a review of the quality and results of the available evidence. The recommendation don't assess any risk of bias related to the study designs of the supporting evidence, not describes the consistency of the results. *Item 2: The recommendations address a health problem that is relevant to the intended target users. Also there is an alignment between target user's scope of practice and targeted patients *Item 3: The outcomes that are relevant to the targeted patients/populations are not clear enough. but this recommendation describes some important points *Item 4: It is not clear that they directly assess the values and preferences of the directly.guide's target users. *Item 5: The values and preferences of the target population have not been sought or considered. *Item 7: Not adressed. *Item 8: This recommendation is aligned with the implementation goals of the guideline *Item 9: It is not clear that the recommendation assessed the setting, and/or the health system in which they are being implemented. 	Canadian_Pressure Chapter: Page: 77	ulcers, 20 Reassessm
37	6.17: Education about the need	2	3	5	1	1	l I	1	1	5	5	2,7	*Item 1: there is not a review of the quality and results of the available evidence. The recommendation	Canadian_Pressure	ulcers, 20
	for regular reassessment Educate the individual with spinal cord injury to monitor the condition of seating equipment and support surfaces regularly to ensure the equipment remains effective for pressure management.							-	-	-	-		 don't assess any risk of bias related to the study designs of the supporting evidence, not describes the consistency of the results. *Item 2: The recommendations address a health problem that is relevant to the intended target users. Also there is an alignment between target user's scope of practice and targeted patients. However not only the patients have to ensure the condition of seating. *Item 3: The outcomes that are relevant to the targeted patients/populations are not clear enough. but the introduction of this recommendation describes some important points regarding this item. *Item 4: It is not clear that they directly assess the values and preferences of the directly guide's target users. *Item 5: The values and preferences of the target population have not been sought or considered. *Item 7: Not adressed. *Item 8: This recommendation is aligned with the implementation goals of the guideline *Item 9: It is not clear that the recommendation assessed the setting in which they are being implemented. However they said 'As healthcare system changes have resulted in shorter rehabilitation stays, it is important periodically to reassess the suitability of the equipment chosen initially'. 	Chapter: Reassessr systems Page: 127	
	 6.10: Cushion maintenance Teach the individual with spinal cord injury and the caregiver to: - Care for and maintain the wheelchair cushion - Monitor the cushion for signs of wear at an appropriate frequency - Set up the cushion properly, including orientation and monitoring for bottoming out - Replace the cushion if it is deteriorating - Avoid placing additional layers on top of the cushion unless deemed essential Aging changes affecting the skin can increase susceptibility to 		4	5	1	1		1	L .	5	1	2,6	 *Item 1: it is not very clear if there was a evaluation of the quality of the available evidence. However, they said Research has not evaluated the performance characteristics of all cushion types and they cited some articles. *Item 2: The recommendations address a health problem that is relevant to the intended target users. Also there is an alignment between target user's scope of practice and targeted patients *Item 3: The outcomes that are relevant to the targeted patients/populations are approach. (for ex. function) *Item 4: It is not clear that they directly assess the values and preferences of the directly guide's target users. *Item 5: The values and preferences of the target population have not been sought or considered. However they recommed to understanding the individual: The clinician gathers information during the assessment to understand the person, relevant issues, goals, functional abilities, lifestyle, and specific needs. *Item 7: Not adressed. *Item 8: This recommendation is aligned with the implementation goals of the guideline *Item 9: It is not clear that the recommendation assessed the setting in which they are being implemented. However they said 'As healthcare system changes have resulted in shorter rehabilitation stays, it is important periodically to reassess the suitability of the equipment chosen initially'. 		ulcers, 20 hair cushic

	pressure ulcer development, and routine reassessment can ensure																
	that cushion choice remains																
	appropriate.																
39	6.18: Schedule for periodic	2 4	1 5	5	1	1	1	l	1	5	5	2.	.8 *	*Item 1: there is not a review of the quality and results of the available evidence. The recommendation	Canadian Press	sure ulcers.	2013
	reassessment											ĺ		lon't assess any risk of bias related to the study designs of the supporting evidence, not describes the	Chapter: Reas	ssessment of	seating
	Establish a mechanism for													consistency of the results.	systems		Ũ
	regular reassessment of													Item 2: The recommendations address a health problem that is relevant to the intended target users. Also	Page: 127		
	performance of sitting support												ť	here is an alignment between target user's scope of practice and targeted patients	Ū.		
	surfaces specific to pressure												*	*Item 3: The outcomes that are relevant to the targeted patients/populations are clear.			
	ulcer prevention and treatment.												*	*Item 4: It is not clear that they directly assess the values and preferences of the directly guide's target			
	Schedule reassessment at least												U	isers.			
	every 2 years, or sooner if any of													*Item 5: The values and preferences of the target population have not been sought or considered.			
	the following occur:													*Item 6: The values and preferences of decision/policy makers are not addressed.			
	- Health status changes,													*Item 7: Not adressed.			
	including weight or medical													*Item 8: This recommendation is aligned with the implementation goals of the guideline			
	changes													*Item 9: It is not clear that the recommendation assessed the setting in which they are being implemented.			
	- Changes in functional status													However they said 'As healthcare system changes have resulted in shorter rehabilitation stays, it is			
	- Equipment wear or disrepair												i	mportant periodically to reassess the suitability of the equipment chosen initially'.			
	- Pressure ulcer development																
	- Changes in living situation																
40	1.10.7 Discuss with the person,	6 (5	5	1	1	1	L	7	5	6	4,		"Item 1: The evidence review was designed to assess the long-term risks that are attached to the use of	NICE_Urinary	incontinence	
	and their family members and													lifferent LUT management systems. The GDG considered that the outcomes under consideration are of	Chapter:		1.10
	carers, that there may be an												h	high importance. The majority of studies were retrospective reviews of medical records. The	Page: 39		
	increased risk of bladder cancer													nonrandomised comparisons between different catheterisation methods were prone to confounding from			
	in people with neurogenic lower													in-standardised management strategies being used for different population groups with different baseline			
	urinary tract dysfunction, in particular those with a long													isk profiles. Studies were therefore categorised as very low quality. Studies were mainly restricted to			
	history of neurogenic lower													batients with spinal cord injury. *Item 2: The recommendations address a health problem that is relevant to the intended target users. Also			
	urinary tract dysfunction and													here is an alignment between target user's scope of practice and targeted patients			
	complicating factors, such as													*Item 3: The outcomes that are relevant to the targeted patients/populations are approach.			
	recurrent urinary tract infections.													*Item 4: It is not clear that they directly assess the values and preferences of the directly guide's target			
	Tell them the symptoms to look													seers.			
	out for (especially haematuria)												-	*Item 5: The values and preferences of the target population have not been sought or considered. Howeve			
	that mean they should see a													hey recommended to understanding the individual.			
	healthcare professional.													*Item 6: The values and preferences of decision/policy makers are not addressed.			
	ficalitatio professional.													*Item 7: The recommendations were made on the basis of the information that arose from the literature			
														eview and the clinical experience of the Guideline development group			
														*Item 8: This recommendation is aligned with the implementation goals of the guideline			
														⁴ Item 9: It is not clear that the recommendation assessed the setting in which they are being implemented.			
		1 1			1									setting in which and be been and the beam of the beam	1		